On September 1, 2025, President Trump called for transparency regarding pharmaceutical companies, specifically Pfizer, and their data on COVID-19 vaccines. He expressed doubts about their reported success and demanded public access to the data. In response, on September 8, Pfizer released results from a Phase 3 clinical trial for its new COVID-19 vaccine but faced criticism.
1. Trump's Demands for Transparency:
• President Trump publicly requested that Pfizer and other drug companies justify the success of their COVID-19 vaccines.
• He highlighted a lack of public access to the data he has seen and questioned the credibility of the reports being shared.
2. Pfizer's Press Release:
• Pfizer announced positive results from its latest mRNA vaccine trial, indicating it produced a strong antibody response among participants aged 65 and older, and younger adults with health conditions.
• However, critics argue the release is misleading and lacks comprehensive data, including the raw data requested by Trump.
3. Criticism of Pfizer:
• The authors claim Pfizer has a history of fraud, with numerous offenses and significant penalties amounting to over $11 billion.
• They assert that Pfizer's claims about antibody responses do not necessarily equate to actual immunity against COVID-19, emphasizing that vaccines should not be solely judged by antibody production.
4. Deceptive Practices:
• The authors highlight that a robust antibody response does not guarantee protection from disease, warning that this misleading notion is a common tactic in the vaccine industry.
• They argue that there are more complex factors involved in effective immunity than just antibody levels.
5. Questioning Pfizer's Credibility:
• The authors challenge the reliability of Pfizer’s reported results, suggesting that the company is not transparent and may be downplaying risks.
• They express concern that without full disclosure of data, trust in Pfizer’s claims remains unearned.
The discussion centers on President Trump's call for transparency and Pfizer’s responses to criticisms about their COVID-19 vaccine data. The article argues that Pfizer's claims are suspect, due to its historical issues with fraud and the dubious correlation between antibody production and actual immunity. The authors stress the need for complete transparency to earn public trust and to clarify ongoing debates regarding vaccine effectiveness.
https://brownstone.org/articles/5-reasons-pfizers-reply-to-president-trump-is-complete-rubbish/
No comments:
Post a Comment